---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-001743"
form_type: "8-K"
ticker: null
cik: "0001844280"
company_name: "Thorne Healthtech, Inc."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T01:18:22.859265+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Thorne HealthTech acquires PreCon Health for $5M cash to bolster brain health portfolio

## Summary
- Acquired all outstanding shares of PreCon Health on Jan 31, 2023, for $5.0M in cash.
- Deal provides access to PreCon's brain health products, IP, and top-tier Medical and Scientific Advisory Board.
- Thorne and PreCon previously partnered in 2021 to launch SynaQuell and SynaQuell+ supplements.
- Thorne may pay future royalties to Eigenlyfe on certain supplement sales upon meeting profit criteria.
- Ongoing Mayo Clinic clinical trials (NCT05041192, NCT05498818) study SynaQuell's effect on brain function.

## SEC filing metadata
- accession: 0000950170-23-001743
- form_type: 8-K
- cik: 0001844280
- company_name: Thorne Healthtech, Inc.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844280/000095017023001743/0000950170-23-001743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844280/000095017023001743/thrn-20230131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-001743
- JSON: https://secwatch.observer/filing/0000950170-23-001743.json
- Plain text: https://secwatch.observer/filing/0000950170-23-001743.txt

## Key facts
- M&A Transactions
  Thorne Healthtech, Inc. completed an acquisition involving PreCon Acquisition LLC for $5.0 million in cash (closed 2023-01-31).
  - Action: acquisition
  - Counterparty: PreCon Acquisition LLC
  - Consideration: $5.0 million in cash
  - Closing: 2023-01-31
  source text: (the “Purchase Agreement”) with PreCon Acquisition LLC, the holder of the Shares and Eigenlyfe LLC (“Eigenlyfe”). Thorne acquired the Shares for an aggregate purchase price of $5.0 million in cash. Thorne will also be obligated to pay royalties to Eigenlyfe on sales of certain nutritional supplements upon achieving certain profit criteria, as described in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844280/000095017023001743/0000950170-23-001743-index.htm
- Material Agreements
  Thorne Healthtech, Inc. entered into Purchase Agreement with PreCon Acquisition LLC and Eigenlyfe LLC valued at $5.0 million (effective 2023-01-31).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: PreCon Acquisition LLC and Eigenlyfe LLC
  - Value: $5.0 million
  - Effective: 2023-01-31
  source text: On January 31, 2023, Thorne HealthTech, Inc. (“Thorne”, or the “Company”), acquired all of the outstanding shares (the “Shares”) of PreCon Health, Inc., a Delaware corporation (“PreCon”), pursuant to a stock purchase agreement (the “Purchase Agreement”) with PreCon Acquisition LLC, the holder of the Shares and Eigenlyfe LLC (“Eigenlyfe”). Thorne acquired the Shares for an aggregate purchase price of $5.0 million in cash.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844280/000095017023001743/0000950170-23-001743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.